Business
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AMLSAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced the results of its reconvened annual and special
About this update from Hanmi Pharmaceutical Co., Ltd.
[{"type":"image","alt":"Aptose Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aptose Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W_19l.RGaQd7rMmL1joc4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d","width":300,"height":112}},"lazy":false},{"type":"text","content":"Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML","length":130,"tagName":"p"},{"type":"text","content":"SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced the results of its reconvened annual and special meeting of shareholders (the “Meeting”) held on August 22, 2025.","length":435,"tagName":"p"},{"type":"text","content":"At the Meeting, shareholders voted in favor of the appointment of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.","length":158,"tagName":"p"},{"type":"text","content":"“We are pleased to welcome Ernst & Young as our new auditor,” said Fletcher Payne, Senior Vice President and Chief Financial Officer & Chief Business Officer of Aptose. “Their global expertise and deep experience in the life sciences sector will support our continued growth and commitment to transparency.”","length":315,"tagName":"p"},{"type":"text","content":"EY is a Big Four global accounting firm that offers a complete spectrum of tax, assurance, and advisory services; they have been selected due to their expertise, capabilities, fit, and understanding of the Company’s industry and business.","length":238,"tagName":"p"},{"type":"text","content":"The Company also announced that it has received an additional advance of US$1.5 million in funding from Hanmi Pharmaceutical Co. Ltd. (“Hanmi”), as part of a US$8.5M loan facility agreement with Hanmi (the “Loan Agreement”) announced on June 20, 2025 (press release here). T...